Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -162.93% is 26% above its 5-year average of -220.25%, around the middle of its 5-year range (-411.19%–-44.03%).
As of the fiscal period ended Wednesday, December 31, 2025. 43.24% above its 12-month average of -287.06%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2025 (2025-12-31): 23.79%.
RETURN ON ASSETS (ROA)
-162.93%
RETURN ON ASSETS (ROA) AVG TTM
-287.06%
RETURN ON ASSETS (ROA) AVG 3Y
-300.16%
RETURN ON ASSETS (ROA) AVG 5Y
-220.25%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+43.24%
CURRENT VS 3Y AVG
+45.72%
CURRENT VS 5Y AVG
+26.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
-480.96%
vs the sector median at left
Apollomics, Inc.
Market Cap
$54.90M
Return on Assets (ROA)
-162.93%
TTM Avg
-287.06%
3Y Avg
-300.16%
5Y Avg
-220.25%
Market Cap
$56.10M
Return on Assets (ROA)
-98.94%
TTM Avg
-57.19%
3Y Avg
-57.75%
5Y Avg
-128.29%
Market Cap
$53.13M
Return on Assets (ROA)
-44.77%
TTM Avg
-25.55%
3Y Avg
-81.14%
5Y Avg
-76.43%
Market Cap
$53.01M
Return on Assets (ROA)
-34.52%
TTM Avg
-27.74%
3Y Avg
-32.72%
5Y Avg
-28.49%
Market Cap
$52.99M
Return on Assets (ROA)
N/A
TTM Avg
-109.69%
3Y Avg
-346.56%
5Y Avg
-277.44%
Market Cap
$57.33M
Return on Assets (ROA)
-54.01%
TTM Avg
-81.00%
3Y Avg
-93.15%
5Y Avg
-65.68%
Market Cap
$51.72M
Return on Assets (ROA)
-22.27%
TTM Avg
-102.93%
3Y Avg
-118.23%
5Y Avg
-95.88%
Market Cap
$51.61M
Return on Assets (ROA)
5.76%
TTM Avg
13.86%
3Y Avg
7.25%
5Y Avg
29.75%
Market Cap
$51.51M
Return on Assets (ROA)
-127.67%
TTM Avg
-99.17%
3Y Avg
-76.90%
5Y Avg
-71.83%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apollomics, Inc. (APLM) | $54.90M | -162.93% | -287.06% | -300.16% | -220.25% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $56.10M | -98.94% | -57.19% | -57.75% | -128.29% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $53.13M | -44.77% | -25.55% | -81.14% | -76.43% |
| ImageneBio Inc (IMA)vs › | $53.01M | -34.52% | -27.74% | -32.72% | -28.49% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.99M | N/A | -109.69% | -346.56% | -277.44% |
| Spectral AI, Inc. (MDAI)vs › | $57.33M | -54.01% | -81.00% | -93.15% | -65.68% |
| Microbot Medical Inc. (MBOT)vs › | $51.72M | -22.27% | -102.93% | -118.23% | -95.88% |
| biote Corp. (BTMD)vs › | $51.61M | 5.76% | 13.86% | 7.25% | 29.75% |
| eXoZymes, Inc. (EXOZ)vs › | $51.51M | -127.67% | -99.17% | -76.90% | -71.83% |
| INmune Bio, Inc. (INMB)vs › | $51.28M | -68.60% | -124.17% | -83.59% | -65.75% |
ROA
-162.9%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -162.93% |
| 2024-12-31 | -411.19% |
| 2023-12-31 | -311.63% |
| 2022-12-31 | -314.89% |
| 2021-12-31 | -76.80% |
| 2020-12-31 | -44.03% |
| 2019-12-31 | -58.07% |
